NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN) Stock Price
NRSNStock
$0.38−68.03%52W
Market Cap$14.44M
P/E—
PEG Ratio—
Div yield—
Beta1.56
NRSN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-67.28%
Price vs S&P 500 (4W)-35.88%
VGM Score15.97
NRSN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRSNNeuroSense Therapeutics Ltd. Ordinary Shares | — | — | F | $0.38 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About NeuroSense Therapeutics Ltd. Ordinary Shares
NeuroSense Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved generic drugs—ciprofloxacin and celecoxib—in a proprietary fixed-dose combination designed to treat these conditions.